Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs placebo as add-on to standard therapy for autoimmune non-infectious uveitis
2020-000754-97Phase 4Unknown
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in uveitis comparing Adalimumab add-on to standard therapy with Placebo add-on to standard therapy (2 arms). Primary endpoint: Time to first treatment failure. Status: unknown.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on 2020-000754-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000754-97.